Lurbinectedin Patent Expiration

Lurbinectedin is Used for treating small cell lung cancer in adult patients who have progressed on or after platinum-based chemotherapy. It was first introduced by Jazz Pharmaceuticals Ireland Ltd in its drug Zepzelca on Jun 15, 2020.


Lurbinectedin Patents

Given below is the list of patents protecting Lurbinectedin, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Zepzelca US7763615 Ecteinascidin analogs for use as antitumour agents Dec 13, 2029 Jazz



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Lurbinectedin's patents.

Given below is the list recent legal activities going on the following patents of Lurbinectedin.

Activity Date Patent Number
Patent litigations
Patent Term Extension Certificate 17 Oct, 2023 US7763615
Electronic Review 06 Jun, 2023 US7763615
Notice of Final Determination -Eligible 15 May, 2023 US7763615
Notice of Final Determination -Eligible 25 Jan, 2023 US7763615
FDA Final Eligibility Letter 29 Aug, 2022 US7763615
Payment of Maintenance Fee, 12th Year, Large Entity 12 Jan, 2022 US7763615
transaction for FDA Determination of Regulatory Review Period 05 Nov, 2021 US7763615
Second letter to regulating agency to determine regulatory review period 20 May, 2021 US7763615
Letter from FDA or Dept of Agriculture re PTE application 14 Dec, 2020 US7763615
Initial letter Re: PTE Application to regulating agency 17 Nov, 2020 US7763615


Lurbinectedin's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List